These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25815144)

  • 41. GPR40 partial agonists and AgoPAMs: Differentiating effects on glucose and hormonal secretions in the rodent.
    Pachanski MJ; Kirkland ME; Kosinski DT; Mane J; Cheewatrakoolpong B; Xue J; Szeto D; Forrest G; Miller C; Bunzel M; Plummer CW; Chobanian HR; Miller MW; Souza S; Thomas-Fowlkes BS; Ogawa AM; Weinglass AB; Di Salvo J; Li X; Feng Y; Tatosian DA; Howard AD; Colletti SL; Trujillo ME
    PLoS One; 2017; 12(10):e0186033. PubMed ID: 29053717
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structural basis for the agonist action at free fatty acid receptor 1 (FFA1R or GPR40).
    Rodrigues DA; Pinheiro PSM; Ferreira TTDSC; Thota S; Fraga CAM
    Chem Biol Drug Des; 2018 Mar; 91(3):668-680. PubMed ID: 29068547
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discovery of novel pyrrole-based scaffold as potent and orally bioavailable free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
    Li Z; Pan M; Su X; Dai Y; Fu M; Cai X; Shi W; Huang W; Qian H
    Bioorg Med Chem; 2016 May; 24(9):1981-7. PubMed ID: 27020683
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A selective GPR40 (FFAR1) agonist LY2881835 provides immediate and durable glucose control in rodent models of type 2 diabetes.
    Chen Y; Song M; Riley JP; Hu CC; Peng X; Scheuner D; Bokvist K; Maiti P; Kahl SD; Montrose-Rafizadeh C; Hamdouchi C; Miller AR
    Pharmacol Res Perspect; 2016 Dec; 4(6):e00278. PubMed ID: 28097011
    [TBL] [Abstract][Full Text] [Related]  

  • 45. GPR40 is partially required for insulin secretion following activation of beta3-adrenergic receptors.
    Pang Z; Wu N; Zhang X; Avallone R; Croci T; Dressler H; Palejwala V; Ferrara P; Tocci MJ; Polites HG
    Mol Cell Endocrinol; 2010 Aug; 325(1-2):18-25. PubMed ID: 20416356
    [TBL] [Abstract][Full Text] [Related]  

  • 46. SAR Studies of Indole-5-propanoic Acid Derivatives To Develop Novel GPR40 Agonists.
    Yoon DO; Zhao X; Son D; Han JT; Yun J; Shin D; Park HJ
    ACS Med Chem Lett; 2017 Dec; 8(12):1336-1340. PubMed ID: 29259758
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
    Hamdouchi C; Kahl SD; Patel Lewis A; Cardona GR; Zink RW; Chen K; Eessalu TE; Ficorilli JV; Marcelo MC; Otto KA; Wilbur KL; Lineswala JP; Piper JL; Coffey DS; Sweetana SA; Haas JV; Brooks DA; Pratt EJ; Belin RM; Deeg MA; Ma X; Cannady EA; Johnson JT; Yumibe NP; Chen Q; Maiti P; Montrose-Rafizadeh C; Chen Y; Reifel Miller A
    J Med Chem; 2016 Dec; 59(24):10891-10916. PubMed ID: 27749056
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of berberine as a novel agonist of fatty acid receptor GPR40.
    Rayasam GV; Tulasi VK; Sundaram S; Singh W; Kant R; Davis JA; Saini KS; Ray A
    Phytother Res; 2010 Aug; 24(8):1260-3. PubMed ID: 20658575
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles.
    Wang Y; Liu JJ; Dransfield PJ; Zhu L; Wang Z; Du X; Jiao X; Su Y; Li AR; Brown SP; Kasparian A; Vimolratana M; Yu M; Pattaropong V; Houze JB; Swaminath G; Tran T; Nguyen K; Guo Q; Zhang J; Zhuang R; Li F; Miao L; Bartberger MD; Correll TL; Chow D; Wong S; Luo J; Lin DC; Medina JC
    ACS Med Chem Lett; 2013 Jun; 4(6):551-5. PubMed ID: 24900707
    [TBL] [Abstract][Full Text] [Related]  

  • 50. GPR40, a free fatty acid receptor on pancreatic beta cells, regulates insulin secretion.
    Itoh Y; Hinuma S
    Hepatol Res; 2005 Oct; 33(2):171-3. PubMed ID: 16214394
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discovery of LY3104607: A Potent and Selective G Protein-Coupled Receptor 40 (GPR40) Agonist with Optimized Pharmacokinetic Properties to Support Once Daily Oral Treatment in Patients with Type 2 Diabetes Mellitus.
    Hamdouchi C; Maiti P; Warshawsky AM; DeBaillie AC; Otto KA; Wilbur KL; Kahl SD; Patel Lewis A; Cardona GR; Zink RW; Chen K; Cr S; Lineswala JP; Neathery GL; Bouaichi C; Diseroad BA; Campbell AN; Sweetana SA; Adams LA; Cabrera O; Ma X; Yumibe NP; Montrose-Rafizadeh C; Chen Y; Miller AR
    J Med Chem; 2018 Feb; 61(3):934-945. PubMed ID: 29236497
    [TBL] [Abstract][Full Text] [Related]  

  • 52. GPR40 (FFAR1) - Combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo.
    Hauge M; Vestmar MA; Husted AS; Ekberg JP; Wright MJ; Di Salvo J; Weinglass AB; Engelstoft MS; Madsen AN; Lückmann M; Miller MW; Trujillo ME; Frimurer TM; Holst B; Howard AD; Schwartz TW
    Mol Metab; 2015 Jan; 4(1):3-14. PubMed ID: 25685685
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Loss-of-function mutation of the GPR40 gene associates with abnormal stimulated insulin secretion by acting on intracellular calcium mobilization.
    Vettor R; Granzotto M; De Stefani D; Trevellin E; Rossato M; Farina MG; Milan G; Pilon C; Nigro A; Federspil G; Vigneri R; Vitiello L; Rizzuto R; Baratta R; Frittitta L
    J Clin Endocrinol Metab; 2008 Sep; 93(9):3541-50. PubMed ID: 18583466
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lack of GPR40/FFAR1 does not induce diabetes even under insulin resistance condition.
    Matsuda-Nagasumi K; Takami-Esaki R; Iwachidow K; Yasuhara Y; Tanaka H; Ogi K; Nakata M; Yano T; Hinuma S; Taketomi S; Odaka H; Kaisho Y
    Diabetes Obes Metab; 2013 Jun; 15(6):538-45. PubMed ID: 23331570
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multiple mechanisms of GW-9508, a selective G protein-coupled receptor 40 agonist, in the regulation of glucose homeostasis and insulin sensitivity.
    Ou HY; Wu HT; Hung HC; Yang YC; Wu JS; Chang CJ
    Am J Physiol Endocrinol Metab; 2013 Mar; 304(6):E668-76. PubMed ID: 23341496
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Improving the Pharmacokinetics of GPR40/FFA1 Full Agonists.
    Du X; Dransfield PJ; Lin DC; Wong S; Wang Y; Wang Z; Kohn T; Yu M; Brown SP; Vimolratana M; Zhu L; Li AR; Su Y; Jiao X; Liu JJ; Swaminath G; Tran T; Luo J; Zhuang R; Zhang J; Guo Q; Li F; Connors R; Medina JC; Houze JB
    ACS Med Chem Lett; 2014 Apr; 5(4):384-9. PubMed ID: 24900845
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,5-dimethylisoxazole.
    Yang L; Zhang J; Si L; Han L; Zhang B; Ma H; Xing J; Zhao L; Zhou J; Zhang H
    Eur J Med Chem; 2016 Jun; 116():46-58. PubMed ID: 27054485
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery of a GPR40 Superagonist: The Impact of Aryl Propionic Acid α-Fluorination.
    Huang H; Meegalla SK; Lanter JC; Winters MP; Zhao S; Littrell J; Qi J; Rady B; Lee PS; Liu J; Martin T; Lam WW; Xu F; Lim HK; Wilde T; Silva J; Otieno M; Pocai A; Player MR
    ACS Med Chem Lett; 2019 Jan; 10(1):16-21. PubMed ID: 30655940
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term in vitro treatment of INS-1 rat pancreatic β-cells by unsaturated free fatty acids protects cells against gluco- and lipotoxicities via activation of GPR40 receptors.
    Tuo Y; Feng DD; Wang DF; Sun J; Li SB; Chen C
    Clin Exp Pharmacol Physiol; 2012 May; 39(5):423-8. PubMed ID: 22332921
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes.
    Leifke E; Naik H; Wu J; Viswanathan P; Demanno D; Kipnes M; Vakilynejad M
    Clin Pharmacol Ther; 2012 Jul; 92(1):29-39. PubMed ID: 22669289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.